Role of molecular subtype in predicting outcome of AIDS-related diffuse large B-cell lymphoma

Journal of Clinical Oncology

Volumn 28, Issue 16, 2010, Pages

  Dunleavy, Kieron ^a   Wilson, Wyndham H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PREDNISONE; PROTEIN BCL 10; RITUXIMAB; TUMOR MARKER; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER SURVIVAL; EPSTEIN BARR VIRUS; FOLLOW UP; GENE EXPRESSION PROFILING; GERMINAL CENTER; HISTOGENESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LETTER; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME; TUMOR BIOPSY; B CELL LYMPHOMA; COHORT ANALYSIS; FEMALE; GENETICS; HOSPITALIZATION; MALE; MOLECULAR BIOLOGY; MORTALITY; NOTE; PATHOLOGY; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; FEMALE; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MOLECULAR BIOLOGY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77954932834     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.7087     Document Type: Letter

References (13)

1. Chadburn A, Chiu A, Lee JY, et al: Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol 27:5039-5048, 2009
2. Kaplan LD, Lee JY, Ambinder RF, et al: Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium trial 010. Blood 106:1538-1543, 2005 (Pubitemid 41208563)
3. Hans CP, Weisenburger DD, Greiner TC, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2003-2005-1545, 2003
4. Lenz G, Wright G, Dave SS, et al: Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359:2313-2323, 2008
5. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
6. Wilson WH, Dunleavy K, Pittaluga S, et al: Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 26:2717-2724, 2008
7. Dunleavy K, Little RF, Pittaluga S, et al: The role of tumor histogenesis, FDG-PET, and short course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood [epub February 3, 2010]
8. Grulich AE, Vajdic CM, Cozen W: Altered immunity as a risk factor for non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 16:405-408, 2007 (Pubitemid 46548641)
9. Dunleavy K, Pittaluga S, Czuczman MS, et al: Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113:6069-6076, 2009
10. Davis RE, Brown KD, Siebenlist U, et al: Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194:1861-1874, 2001
11. Lenz G, Davis RE, Ngo VN, et al: Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319:1676-1679, 2008 (Pubitemid 351432507)
12. Ngo VN, Davis RE, Lamy L, et al: A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441:106-110, 2006
13. Lam LT, Davis RE, Pierce J, et al: Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 11:28-40, 2005 (Pubitemid 40075775)